3.2800
+0.0100
+(0.31%)
At close: 3:04:12 PM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
425,621.2859
420,643.6192
373,440.3568
315,134.2490
514,885.2874
Cost of Revenue
297,149.0356
285,645.9640
239,834.6978
195,758.0343
254,580.0092
Gross Profit
128,472.2503
134,997.6553
133,605.6591
119,376.2147
260,305.2782
Operating Expense
135,276.0253
161,037.0734
142,770.1920
242,351.5593
318,920.9584
Operating Income
-6,803.7749
-26,039.4181
-9,164.5329
-122,975.3446
-58,615.6802
Net Non Operating Interest Income Expense
-22,394.7039
-33,429.0076
-41,212.6779
-46,835.2184
-58,890.6272
Pretax Income
-16,660.1130
-11,563.6776
-135,317.8426
-224,162.7027
28,398.0992
Tax Provision
-63.2317
313.2883
-2,628.0875
4,117.6117
1,123.1117
Net Income Common Stockholders
-16,596.8813
-11,876.9659
-132,689.7551
-228,280.3144
27,274.9875
Basic EPS
-0.03
-0.02
-0.25
-0.43
0.05
Diluted EPS
-0.03
-0.02
-0.25
-0.43
0.05
Basic Average Shares
646,183.1900
593,848.2960
530,759.0200
530,884.4520
545,499.7500
Diluted Average Shares
646,183.1900
593,848.2960
530,759.0200
530,884.4520
545,499.7500
Total Operating Income as Reported
-17,363.9008
-63,453.2904
-116,574.5344
-199,342.1283
51,089.3797
Rent Expense Supplemental
--
265.4628
373.4509
1,387.7949
4,198.2108
Total Expenses
432,425.0608
446,683.0373
382,604.8898
438,109.5936
573,500.9676
Net Income from Continuing & Discontinued Operation
-16,596.8813
-11,876.9659
-132,689.7551
-228,280.3144
27,274.9875
Normalized Income
-12,630.4388
-7,362.6679
-67,151.7132
-201,692.6580
-131,647.2318
Interest Income
10,388.2062
14,049.3181
11,143.7446
10,068.6495
9,224.5744
Interest Expense
35,697.2191
47,457.8305
52,311.1272
56,872.7887
68,072.9738
Net Interest Income
-22,394.7039
-33,429.0076
-41,212.6779
-46,835.2184
-58,890.6272
EBIT
19,037.1061
35,894.1529
-83,006.7153
-167,289.9140
96,471.0730
EBITDA
19,037.1061
74,599.2175
-41,392.7419
-123,512.1493
145,773.9443
Reconciled Cost of Revenue
297,149.0356
285,645.9640
239,834.6978
195,758.0343
254,580.0092
Reconciled Depreciation
--
38,705.0646
41,613.9734
43,777.7648
49,302.8713
Net Income from Continuing Operation Net Minority Interest
-16,596.8813
-11,876.9659
-132,689.7551
-228,280.3144
27,274.9875
Total Unusual Items Excluding Goodwill
-3,981.5541
-6,019.0641
-66,836.1052
-35,450.2086
165,466.2149
Total Unusual Items
-3,981.5541
-6,019.0641
-66,836.1052
-35,450.2086
165,466.2149
Normalized EBITDA
23,018.6601
80,618.2816
25,443.3633
-88,061.9407
-19,692.2706
Tax Rate for Calcs
0.0000
0.0003
0.0000
0.0003
0.0000
Tax Effect of Unusual Items
-15.1116
-1,504.7660
-1,298.0633
-8,862.5521
6,543.9956
12/31/2020 - 3/16/2010
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
002437.SZ HARBIN GLORIA PHARMACEUTICALS Co., LTD
2.4900
-0.80%
002390.SZ Guizhou Xinbang Pharmaceutical Co., Ltd.
3.9300
-5.76%
600664.SS Harbin Pharmaceutical Group Co., Ltd.
3.7100
0.00%
TRILC.IS Turk Ilac Ve Serum Sanayi Anonim Sirketi
17.34
-1.48%
600518.SS Kangmei Pharmaceutical Co., Ltd.
2.2200
0.00%
600789.SS Shandong Lukang Pharmaceutical Co.,Ltd.
8.90
-0.45%
PYFA.JK PT Pyridam Farma Tbk
216.00
-1.82%